Document: Presentations/hjnw0257.zip/hjnw0257.pdf
Category: Presentations
Processed: 2025-06-12T12:13:17.773162
Method: pymupdf+enhanced_ocr
Text Length: 24600 chars
==================================================

=== Page 1 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257

=== Page 1 Image 1 (OCR) ===
& Company EEE Wy

Corporate
performance
diagnostics

Discussion document
March 2020

@endo Y L

td J Wh
eg / f
OLE DEE T AL ALD PROPR E TARY. FAP SES J
Ang) asi Dns ake gs wltcabsres Dorin seca PR: Kosin Rss ran OC ae Sf bs ff)
ssbety pratt Ct ho

MCK-MAAG-2627981

=== Page 2 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257

=== Page 2 Image 1 (OCR) ===
Key issues

.

Opioid: Company is facing litigation related to opiaid overuse across many states in US Settled liabilities with

Oklahoma and case coming up with NY state Analyst estimate total potential liability range from USD 0 5B - 4 0B

pete tate tere erate et ete a erate a ete ere ete a eR RR RR eR RI RR en eR ne ne nn A nnn A ne a eine a ene eine eimai mie ereierereeierermierete

Legal

pict c enter eter eres

Redacted

Redacted

aerate eee eee eee ere ein eee ee ee ee eRe ee ne nn ne A nn RR en nin RI ee ne a nie nia en ne niente eee nie mia ere ereiereierermi eet

eine teeter eee

sor

vntovy

McKinsey & Company

MCK-MAAG-2627981.000001

=== Page 3 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257

=== Page 3 Image 1 (OCR) ===
Summary

* Endo is well performing operationally with higher margins than peers. However, due to issues related to opioid crisis,

pete re rere ete re te Dieta eter ret eve ei brores

i

i

bore cere eer ege a eis pe ieie tisegiese.

Redacted

'growth is negative, cash flow did not cover liabilities, debt is below investment grade and

peter ete eee eee ete ee ee Re SR Rn RR RR eS A RR Re RR RR RR Re a Re a ee a a ee A a eae a nea ea eieeaeieaeinimiaiermareimeia

Company is tating large potential litigation liabilities

Redacted

aime teint eter ete eter e tere ete eer ererereierererete:

ieee tere eter eter rete a ete ere ete a ete ee a ee ee ne RR ee A nn RR en A nn RR ee Rn a ee ee ne nie aie ein ete eee nina eieeieieimeieieeiaiermarereeie

McKinsey & Company

6 September 2020

MCK-MAAG-2627981 .000002

=== Page 4 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257

=== Page 4 Image 1 (OCR) ===
Summary

nally

h higher margins than peers. However, due to issues related to

* Endo is well performing ope

‘

R

opioid crisis

Fhe eee eee ee re a ee eee

<

growth is negative, cash flow did not cover liabilities, debt is

below investment grade and company

‘acing large potential litigation liabilities

peer e ete e ee eeeeeeREeREREEmEmeeEen Cm m emer tmem mie:

Redacted

ite teint eet eee te erate eee ere ete ee en ee ee ee RR Rn en RR nn RR ne A RI RR en eR Rn nn ne A nn nn ee a nie min eee eimai era eimeiarereiererermierermieiere

McKinsey & Company

6 September 2020

MCK-MAAG-2627981 .000003

=== Page 5 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257

=== Page 5 Image 1 (OCR) ===
Endo’s share price has declined ~90% in last 5 years mainly driven by

legal challenges and underperformance

Endo share price’

USD per share

ee ees

aca mre se imra amie aim  anesarmlarararey

.

SSS eae

120

Mar ‘16: Sued by FTC along

wth others ‘or illegally blocking

Redacted

Redacted

Redacted

prererm sens mseae’

lower-cos: generic versions of

randed drugs Opana

i

!

i

=. aa

Redacted

Uipieierm ming pimieieieiereeimiereieeiedd

Lerminces wqemsn term sm ime nems -

|

|

|

cetera tei erate terete terete

80

patotavavetaiara ate vevaraeerare

Jun ‘17: Sued by Ohio Asorney General

pete tetera terete

alongwith ‘our other pharma companies ‘or

Redacted

‘heir alleged par: in dnung an opioid and

Prescnpion painkiller overdose epidemic

i

ect ete reer eter eter eines

i

i

Redacted

2

Redacted

alate ere iote eral

|

aiaie nsaiota micas nraia ieee

!

through aggressive marke'ing ‘ac‘ics

40 -

eine tetera tere terete eerie:

Jun 17: FDA reques's.

pain medication, Opana

Endo ‘o rerrove rs opioid

ER, ‘ror the marke:

i

Redacte

|

ieee te eee terete re reree

Jan 15

Jul 15

Jan 16

Jul 16

Jan 17

Jul 17

Jan 18

Jul 18

Jan 19

Jul 19

Jan 20

t

7A bet

77

s:

y

SAP Capla Tet rays s

McKinsey & Company

i]

MCK-MAAG-2627981 .000004

=== Page 6 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257

=== Page 6 Image 1 (OCR) ===
Be ee ee ee

Redacted

Tne Ene rn SEnE ESSERE SS SEnE SSDS nSSnE SESE SERS SES SE SERENE SESE SERS SESS SERSSnS SE SESEES DSSS SERESRESOSEASSRESHSSESERESNSSHSnSSRESNSESSSRESSSSHSSESSRESSSSESERSNSSHSRSSRSSSSESERSSSESESSESSSESSSSESERSSSSHSSESSnSSSSESSRESNSSISSESSEE SOSH SESSSESSHSESSESSHSSESSnSNSSHSSISSRESHS=NSInSSNSSOSSnSSRSSESSNSTSSSnESESESERESHSSSSTESSSESHSnSSESSNSSESESESNS DS SEnSSNSSHSSSSESSNE SE SESSEE DESDE SEESONSSOS

AAG-2627981.000005

=== Page 7 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257

=== Page 7 Image 1 (OCR) ===
Be ee ee ee

Redacted

nena rn SEn ESSE Sn SEnE SSS SEn ENE SESn SERS SESS SERSSnE SESE SERS SESS SERSSNSSESNSEESSNSSESERSNESOSEESSRESHSSESERSSNSSESnSSRESSSESSRSSSSSHSEESSRESSSESEnSSNSSISSESSESSSSNSERSSSESHSSESSSESSSSISSnSSNSSHSSESSnSSSSNSSSESNSSUSSESSnE SSSI SERSESSHSnSSESSHSSESSnSNSSHSSnSSRE SSSA SInSSNSSUSSRSSRSSESSNSTSSSNESESESERESSSSSTESSSESHSnSSES DSSS SSSESNS DS SERSSRSSHSSNSISESNE SE SESSES DESDE SERSONSSISS

AAG-2627981.000006

=== Page 8 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257

=== Page 8 Image 1 (OCR) ===
Be ee ee ee

Redacted

nner Ene rn SEn ESSENSE SERS nS SESE RENE SESE SERED SSE SERSSNE SESE SERS SESE SERSSnS SES EESEESSSSESERESNESOSEESSRESHSSESERSSNSSESRSSRESSSESSRESSSOSSESSRESHSSESERSNSSHSESSRS SSDS SERSSSESESSnSSSESSSSSSERSSSSHSSESSnSSSSESSSSSNSSISEASSnESSSESESSSESSHSESSESSSSSSSSSNESHSEASESESN SSE SInSSNSSUSSRSSRSSESSNSTSSSNESESESERESHSSSSTESSSESHSnSSESSSSESSSESNS DS SEnSSRSSHSSNSISSSNE SE SnSSEE DESDE SEESSNSSISS

AAG-2627981.000007

=== Page 9 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257

=== Page 9 Image 1 (OCR) ===
Endo's revenue profile has remained flat and declined since 2016 driven

by both Branded and Gx segments

Endo's Revenue evolution by segment, 2014-19, USD bn, as reported

Sie ratSiciesa re tcie eS

ieee tere eter erate rere rererereie,

Redacted

@ Granded Phamral

a ra

i 1 Genenc 2harra i

etorcceisrecdretetecaietatasciaiaesd

Growth (2014-19),

Key takeaway

CAGR SE

a Ste tereiarersreresesereserery

i

i

40

Redacted

8% p.a.

10% p.a.

Ln areuprninierersieieieiesere!

33

35

Branded Pharma portfolio

declining, driven by loss of

29

29

29

NA

marketing exclusivity for

|

certain drugs and voluntary

withdrawal of OPANA® ER

a

from the market since

FY2017

Fee erate erase ra areca ra a eaey

26

og

23

03

Redacted

05

03

02

20°4

20°9

eine tetera e terete tere rerererered

iene ee ere Nee ee eee ere elm ielem rere seers

‘

Redacted

McKinsey & Company

)

Liece eee ee ete ee ere ete eee erate a ere ere ete eee ere ete eee areata a ee aimee eee ere eierereierermrmreretey -!

MCK-MAAG-2627981 .000008

=== Page 10 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257

=== Page 10 Image 1 (OCR) ===
Be ee ee ee

Redacted

nner nE rn SEnE ESS EnE SSE SEnE SSDS RENE SESE SERE SESS SERSSnE SESE SERS SESS SERSSnESESESEES DSSS SERSRESUSEASSRESHSSISERSSNSSESnSSRESSSSSSRESSSHSSESSRESHSSESERSNSSHSERSSRS SSSI SERSSSESESSESSSESSSSI SERENE SHS SESSnSSSSESSRESNSSHSEASSRESSSNSERSSNSSHSESSRSSOSSESSSSNSSHSSISSRESHSSNSInSSNSSHSSRSSRSSESSNSTSSSNESESESSRESSSSSSTESSSESHSnSSESSHSEESSSESNS SS SEnSSESSHSSNSISSNE SE SnSSEOSSSSESEREONSSOSS

AAG-2627981.000009

=== Page 11 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257

=== Page 11 Image 1 (OCR) ===
Be ee ee ee

Redacted

nee rn SEn ESSERE SSE SEnE SSDS RENE SESE SEnE SESS SERSSnE SESE SERS SES SESERSSNS SES EESEES DSSS SERSRESOSEESSRESESSESERSSNSSESSnSSRESNSESSSRESSSHSSESSRESSSNSERESNSSHSESSnSSSSNSERSSSSSOSSESSSESSSNSEnSSSSHSSESSnSSSSNSSSESNSSUSEASSRESSSESERSSESSHSESSESSHSSESSSSNESHSSESSRESHSSNSTnSSNSSOSSRSSRSSESSNSTSSSNESSSESERESSSSSSTESSSESHSnSSEOSSSESESESNS DS SEnSSRSSHSSNSSNSSNE SES ESSRSSSSSESEESSSOSS

=== Page 12 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257

=== Page 12 Image 1 (OCR) ===
Be ee ee ee

Redacted

nen EnE rn SEnE ESSENSE SEnE DOSS SE RENE SESE SERS SESS SERENE SESE SSNS SESS SERSSnSSESnSEES SSSI SERSRESOSESSRESHSSESERSSNSSESnSSRESSSESSRESSSSHSERSSRESSSESERSNSSHSSRSSRSSHSSN SERENE SOS SESSSESSSNSEnSSNSSHSSESSnSSSSNSSRESNSSISSESSRESHSSESERSNSSHSESSRSSNSSESSSESNSSHSSISSRESNSSNSInSSNSSUSSRSSRSSESSNSTSSSNESESESERESSSSSTESSSESHSnSSESSNSEESSSESNS DS SEnSSRSSHSSNSISSNE SE SESSRS DESDE SERSONSSOS

=== Page 13 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257

=== Page 13 Image 1 (OCR) ===
Be ee ee ee

Redacted

nner Ene rn SEnE ESSERE SSE SERE SSS SERENE SESE SERS SES SE SERENE SESE SERS SESS SERSSNESESASEESSOSSESERSRESOSESSRESHSSISERSSNSSESESSRESOSSSSSRSSSSHSEASSRESSSESERSNSSHSTnSSRS SOSH SERENE SO SSnSSSESSSISERSSNSSHSSESSRSSSSSESSnESNSSHSEESSRESHSSESESSSNSSHSESSEESSSESSnSNSSHSSRSSRESHSSNSTnSSNSSUSSRSSnSSESSNSTSSSNESESESERESHSSSSTESSSE SHS TnSSESSNSEESSSESNE DS SEnSSRSSHSSNSISSSNE SE SnSSRS DESDE SEESONSSOS

=== Page 14 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257

=== Page 14 Image 1 (OCR) ===
Be ee ee ee

Redacted

Tne rn SEnE ESSERE SSE SEnE SSS SERENE SESE SEnE SESE SERSSNE SESE SERS SESS SEnSSnSSESESEES SSSI SERSRESOSESSRESHSSESERSSNSSHSnSSRESSSESSRESSSHSEESSRESHSSESERSNSSHSESSESSOSSESERSSSESUSSESSSESSSISERSSESSHSSESSRSSSSSSSRESNSSISEESSnESSSESERSSESSHSnSSRESOSSESSSSNSSHSSASSEESNSSNSInSSNSSUSSRSSNSSESSNSTSSSNESESESERESSSSSTESSSESHSnSSESSNSSESESESNS DS SEnSSRSSHSSNSESSNE SE SESSRS DESDE SERSOSSOSS

=== Page 15 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257

=== Page 15 Image 1 (OCR) ===
Be ee ee ee

Redacted

Tn ern ne rn SEnE ESSENSE SERS nS SE RENE SESE SEnE SESS SEnSSNE SESE SERS SESS SERSSnS SES EnSEES SSS SSRSRESUSEASSRESSSESERSSNSSESnSSRESNSESSSRSSNSSHSSESSRESHSSESERSNSSISRSSES SOSH SEnSSSESESSESSSESSSESERSSSSHSSESSRSSOSSESSSESNSSISSESSnESHSSESERSSESSHSnSSRSSNSSSSSSESNSSHSSnSSEESSSNSEnSSNS SOS SESSRSSESSNSTSSSNESSSESERESOSSSSTESSSESHSnSSESSNSSNSESESNS DS SEnSSRSSHSSNSISSNE SE SESSRSSSSDESERSNSSIS

=== Page 16 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257

=== Page 16 Image 1 (OCR) ===
Be ee ee ee

Redacted

nner rn SEnE ESSENSE SERS SOS SEn SESS SERS SES SESERSSNE SESE SERS SES SESERSSNESESESEES SSDS SSRSRESUSNSSRESSSESERSSNS SH SnSSRESNSSSSSRESSSHSEESSRESHSSESERSNSSHSESSnS SOSH SEnSSSESESnSSSESSSISERSSNSSHSSESSRSSSSESSSESNSSHSSESSRE SSSI SERSESSHSnSSESSSSSSSnSNSSHSSISSEESHSSNSInSSNSSOSSRSSRSSESSNSTSSSNESESESSRESSSSSSTESSSESHSnSSEESNSENSSSESNS DS SERSSRSSHSSNSESSSNE SE SnSSRS DESDE SEESNSSISS

=== Page 17 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257

=== Page 17 Image 1 (OCR) ===
pine tee tererere,

Endo also has large potential litigation liabilities up to UST recacte

eine tected

Estimate

Liability

Opioid

"If we consider Oklahoma to be a “typical” state (28th in population and 29th in GDP). Endo’s settlement

implies a nationwide liability around $500M.“ — Gabelli. Jan 14°, 2020

"We estimate a fair value range of S2-4 based on our DCF (10% WACC. -1% terminal). using ~$3-4B

mista teeter eee te erate teeter rere ele ere creer iber a: Date cre tie a Perma aia ee NU a ete iaid ete irerb Sree ere aie ere ee eee ereeieieeierermiereieieiay ‘

opioid charges paid over 10 years." - Guggenheim, Nov 5, 2019

i

i

i

i

Redacted

bien re eee eee ee ere eter et ete eee a ete eee ete ete ee ee ee a nn eR ee a nn nn en A nn ee ee a ne nie nie eine nie aie aimee eee aimee eeiereimrerererey =

sor

ssp

vila og Areal:

rl

vt

McKinsey & Company

7

MCK-MAAG-2627981 .000016

=== Page 18 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257

=== Page 18 Image 1 (OCR) ===
Opioid portfolio currently consists of Percocet” that contributes

~14% of Branded Pharma and 4% of company revenue

"PERCOCET™. which is an opioid analgesic approved for the treatment of moderate-to-moderately-severe pain

The Company's pain products, including opioid products. are managed as mature brands and are not and have not been actively promoted for years. In

December 2016, the Company announced the elimination of its entire U.S. pain product field sales force

Generic Pharmaceuticals The Generic Pharmaceuticals segment includes a product portfolio of approximately 150 generic prescription product families

including solid oral extended-release. solid oral immediate-release. liquids, seni-solids, patches (which are medicated adhesive patches designed to deliver the

pharmaceutical through the skin), powders. ophthalmics (which are sterile pharmaceutical preparations administered for ocular conditions) and sprays and

includes products in the pain management. urology. central nervous system disorders, immunosuppression, oncology. women’s health and cardiovascular disease

markets, among others

- 10K 2019

Revenue in USO M

2019

Percocet

116

Branded Pharma

855

Percocet as % of Branded Pharma

14%

Endo total revenue

2.914

Percocet as % of Endo total revenue

4%

sor

wn tov)

18

McKinsey & Company

MCK-MAAG-2627981 .000017

=== Page 19 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257

=== Page 19 Image 1 (OCR) ===
Summary

. Endo i is well performing operationally with higher margins than peers. However, due to issues related to opioid crisis,

monte tere erate eie ere ere etete Bietdie rete

jac

in pete tetera tate rere rete tere eter ererereieres

‘growth i is negative, cash flow did not cover liabilities, debt is below investment grade and

company is facing large potential litigation liabilities

ite teint eter ete eee ere ete eee ere ete eee Re ete ee RR en Rn eR RI RR nn RR RR nn Rn ne A ne a ne ete ee a nie mere mie nie miei ei miereeiererer eerie

Redacted

ite teint eter ete eee ere ete eee ere ete eee Re ete ee RR en Rn eR RI RR nn RR RR nn Rn ne A ne a ne ete ee a nie mere mie nie miei ei miereeiererer eerie

McKinsey & Company

19

6 September 2020

MCK-MAAG-2627981 .000018

=== Page 20 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257

=== Page 20 Image 1 (OCR) ===
Be ee ee ee

Redacted

Tne rn SEnE ESSERE SSE SEnE SSS SERENE SESE SEnE SESE SERSSNE SESE SERS SESS SEnSSnSSESESEES SSSI SERSRESOSESSRESHSSESERSSNSSHSnSSRESSSESSRESSSHSEESSRESHSSESERSNSSHSESSESSOSSESERSSSESUSSESSSESSSISERSSESSHSSESSRSSSSSSSRESNSSISEESSnESSSESERSSESSHSnSSRESOSSESSSSNSSHSSASSEESNSSNSInSSNSSUSSRSSNSSESSNSTSSSNESESESERESSSSSTESSSESHSnSSESSNSSESESESNS DS SEnSSRSSHSSNSESSNE SE SESSRS DESDE SERSOSSOSS

=== Page 21 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257

=== Page 21 Image 1 (OCR) ===
Future cash flows from operations would be used up for litigation

and interest charges and debt repayments

Cumulative cash flow, FY2020-24, USD bn

Upside case

Downside case

oe ta eta ase ete a eter asa re tala arate se ata aia asain ie a aierat a arate: a ates e erates a arate are,

CFO betore interest |

Jimi Siesta Simin siminra Ss ieinre sre ei erie te rpidtniaemis winter sin inia siniarpeaemincmsss lass

Redacted

Assumptions:

pada sn a ane

& changes in WC

|

Lrigation charges

of

|

Redacted

hate ieietataietminraretaieiajeiainiaeimietseieiais setae ta ieiataiaiaiasd areieiaiaseiaintascimsetaeietsisseieis siete,

-

Lcieinieereiase.eieiarn ereiave eeiate crete ae wiasaeereins -

!

Opioid litigation liability estimated to range from

USD 500M In Upside case to USD 4.0B in Downside

case (based on analyst reports), assumed to be

Sa aie EERE ne ee aaa ee ee

repaid by FY2024

Redacted

Redacted

Lcrerereseserarerereiesesereerereresesererntereresesererereseres <

phe a

ate rere re saree te reretasese arn retar esate a arate as e.e a arate asesala arate aiesatarn tata a.eseraareseaseserararere

McKinsey & Company

21

Yen ce can se ce ee oe a a a a oe se se oe a ee ee ee re oe eee ee seem ee eee ares -

Redacted

ieee te eter ete re ere ete ete a ere ere ete ne eR a etn ee eR Re mR nn RR nn RI eR Re IR RRR Re RR nn RR RR ne A Re RR ne A Re ne ee a ne ee en ee nin eee ee a neie nee nineieieieiaeimieieeiaiereererereiered

MCK-MAAG-2627981 .000020

=== Page 22 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257

=== Page 22 Image 1 (OCR) ===
Be ee ee ee

Redacted

Tne nE rn SEn ESSENSE SEnE SSS SERENE SESE SEnE SES SE SERENE SE SEESSnS SESS SERSSNSSESASERS SSDS SERSRESOSEESSRESHSSESERSNSSHSnSSRESSSSSSRESSSHSERSSRESSSESERSNSSHSRSSRSSHSSESERSSSESOSSESSSESSSSNSERSSSSHSSESSnSSSSESSSESNSSISEESSRESHSSESTnSSESSHSnSSRESHSSESSnSNSSHSSnSSRESSSNSEnSSNSSUSSESSRSSESSNSTSSNESESESERESSSSSSTESSSESHSnSSESSNSSESESESNS SS SRSSSSSHSSNSESSNE SES EESSEE DESDE SEESONSSISS

=== Page 23 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257

=== Page 23 Image 1 (OCR) ===
Be ee ee ee

Redacted

Tne rn SEnE ESSERE SSE SEnE SSS SEnEnE SESE SERE SES SESERSSNE SESE SSNS SES SESERSSnSSESnSEES DSSS SERSRESHSESSRESHSSESERSSNSSHSSnSSRESNSSSSSRSSSSHSSESSRESSSESERSNSSHSESSESSSSNSERSSSSSOSSESSSESSSSSERSSSSHSSESSRSSSSSESSnESNSSHSEASSnESSSESERSSNSSHSnOSES SSDS SSSSNESHSEASSEESHSSNSInSSNSSUSSRSSRSSESSNSTSSSNESESESERESSSSSTESSSESHSnSSES SSSI SESESNS DS SEnSSRSSHSSNSEnSSNE SE SESSES SESS SESSSSOSS

AAG-2627981.000022

=== Page 24 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257

=== Page 24 Image 1 (OCR) ===
Be ee ee ee

Redacted

nena EnE ncn ESSENSE SEnE SSDS RENE SESE SEnE SESS SERSSNE SESE SERS SESS SERSSNS SES EESERS SSDS SERSRESOSESSRESSSESERSSNSSESESSRESNSESSSRESSSHSSESSRESSSESERSNSSHSRSSESSSSNSERSSSSSESSESSSESSSSNSEnSSSSHSSESSRSSSSESSRESNSSISSESSnE SSSI SERSSESSHSESSRSSSSSSSSSNSSHSEASSSESHSSNSTnSSNSSOSSRSSRESESSNSTSSSNESESSESERESHSSSSTESSSESHSnSSEOSNSSESESESNS DS SEnSSRSSHSSNSISESNE SE SnSSEE DESDE SEESSSOS

AAG-2627981.000023

=== Page 25 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257

=== Page 25 Image 1 (OCR) ===
Be ee ee ee

Redacted

Tne rn SEnE ESSERE SSE SEnE OSSD RENE SESE SERS SES SESEnSSNE SESE SERS SES SESERSSNSSESESEESSOSSESERESnESOSASSRESSSESERSSNSSHSnSSRESNSSESSRESSSHSEESSRESSSESERSNSSHSESSRSSSSESEnSSSESESSESSSESSSESERSSSSHSSESSnSSSSSSSnESNSSHSEASSnE SSSI SERSSESSHSTESSRESSSESSSSNSSHSSISSEESH SSN STnSSNSSOSSRSSRSSESSNSTSSNESESESERESSSSSTESSSESHSnSSEESNSSESESESNS DS SERSSNESHSSNSISSSNE SES ESSES DESDE SERSOSSISS

AAG-2627981.000024

=== Page 26 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257

=== Page 26 Image 1 (OCR) ===
Fel aentabeentebeliinenrententenbenaenbabmanoenzentabeentebaentanbenoenaa™="<deamante’*shaenaenteabenelnete-saeeinentantentenmetaieenetmtanaieiaianemeermnaanemtieee

Analysts are concerned about Endo's ongoing opioid litigations,

Redacted

sree eet olor ys aia re is ofa eis Slates eiare1s Siereie loses Stores Sto reus ota mie aia reuse oie e is Sines Siete r=

Siateie Siereis Siete ys fore is Stam ys-siare ys Sia reie aia hus Siareis Sine,

©. We are becoming more positive on ENDP from an opioid standpoin

patdvateresdiatlacet sta aveiite tase lai aiare dlatatardtalatalavetatetiieteterSteataversia ecard!

Redacted

Redacted

ieee tere eter eee ere eee re ere ere eierereie areata eee ere eierereierererere:

[i a ae ee a ee =

Gabelli, 14 Jan 2020

[ater Ste tevercieiaretSaieietcieietatsiaietetsialele setae cia leeiiieisretdjalstetcieisletcveleesietatestetavesieiaversteid

petite eter eter eet rete mieny

ee a

Redacted

a oe

Redacted

ieee ee ree ee ee ee ete te ee et ee eee ee mm e meme  mem mmem mtmem re

' However, ENDP st Redacted

a a is

and ongoing opioid litigation/headline risk add unique risks that are challenging to handicap and have weighed on the stock

RBC capital markets, 5" Nov 2019

piesa ler bface debra ia ietye ia terbyacele apeiete npeisie niece en yela er byaceie bine te reyacetertyaceyee

aeeeee

=.=!

' However, we continue to expect this dynamic to be

avsrahadawed by the ongoing opioid saga, which in our view remains a very significant risk given the company's branded

FEES I SSSI SET SENSO CENCIO IOS aE NTES SSS NCRSES SSS SuESnISSSOOSSOE NSE SEISECE NCE OLIIC SS Es SEO -osNCIOEDISSISNCESSSOCOIES Cis SOOESSENCEISOSE SOE CIOS SOLED CSO SOE SESS

opioid Portfolio/mkt share }

Redacted

i

i.

Redact

aie Pe ae A ery eR Oe RO IRE AE NET EL TOI EE BLO IRE OO ee emia remem terme!

i

JP Morgan, 5‘ Nov 2019

Sow

vail

1

McKinsey & Company

26

MCK-MAAG-2627981 .000025

=== Page 27 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257

=== Page 27 Image 1 (OCR) ===
Be ee ee ee

Redacted

nner nE Sn SEn SSSR SEnE SSE SEnE SSE SERENE SESE SEnE SESS SERSSnE SESE SSNS SESS SERSSNSSESESEES SSDS SERSRESOSEESSRESESSE SERENE SE SnSSEESNSSESSRSSNSSHSEESSRESSSESSRSNSSHSRSSESSSSESEnSSSESESSESSSESSSNSERSSSSUSSnSSnSSSSSHSSSSSNSSISEASSRESHSSESTRSSESSHSESSRESSSSSSSSNSSHSERSSSESHSSNSEnSSNSSOSSRSSnSSESSNSTSSSNESSSESERESSSSSSTESSSESHSnSSESSSSESSSESNS DS SEnSSNESHSSNSISSNE SE SESSSESSSSESEREOSSOSS

AAG-2627981.000026

=== Page 28 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257

=== Page 28 Image 1 (OCR) ===
Summary

* Endo is well performing operationally with higher margins than peers. However, due to issues related to opioid crisis,

pare ie eee ect e sierra miei eieteteres

i

baer te ete eee igi e te gin teseeteie pore

Redacted

growth is negative, cash flow did not cover liabilities, debt is below investment grade and

company is facing large potential litigation liabilities

ime ieee mieten rere tere ete ee ete ee en ee Re eR ne RR en eR Rn RR nn eR RI RR ne RR nn Rn RR RI eR nn Re ee ee nn ein ete eine eer eiaieimi ernie mime eie

Redacted

ieee tere eet a ete a ere rete ete ere ere a ete eee nie eR ne RR ee A en RR ne Re RR Re eR nn RR ee Re ne ein ee nie a ein aie ein a aie eta eimaieimieierermimreiereie: i

McKinsey & Company

28

6 September 2020

MCK-MAAG-2627981 .000027

=== Page 29 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257

=== Page 29 Image 1 (OCR) ===
Be ee ee ee

Redacted

nnn nner SERS SEEDS SERS nS SESE nEnE SESE SEnE SESS SERSSNE SESE SSNS SESS SERSSnSSESESEES SSDS SERSRESHSESSRESHSSESERSSNSSESESSRESSSSSSRSSSSHSEESSRESESSESERESESSHSSESSRSSHSSN SERENE SE SSnSSSESOSSSSERSSSSHSSESSRSSSSNSSRESNSSISEASSnESSSESERSSNSSHSESSESSSSESSSSSNSSHSEESSRESH SSN SEnSSNSSUSSRSSRSSESSNSTSSSNESESESERESSSSSTESSSESHSnSSES SSSI SESESNS DS SERSSNSSHSSNSISSNE SE SESSEE SESE SERSOSSOS

AAG-2627981.000028

=== Page 30 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257

=== Page 30 Image 1 (OCR) ===
Be ee ee ee

Redacted

nena EnE ncn ESSENSE SEnE SSDS RENE SESE SEnE SESS SERSSNE SESE SERS SESS SERSSNS SES EESERS SSDS SERSRESOSESSRESSSESERSSNSSESESSRESNSESSSRESSSHSSESSRESSSESERSNSSHSRSSESSSSNSERSSSSSESSESSSESSSSNSEnSSSSHSSESSRSSSSESSRESNSSISSESSnE SSSI SERSSESSHSESSRSSSSSSSSSNSSHSEASSSESHSSNSTnSSNSSOSSRSSRESESSNSTSSSNESESSESERESHSSSSTESSSESHSnSSEOSNSSESESESNS DS SEnSSRSSHSSNSISESNE SE SnSSEE DESDE SEESSSOS

AAG-2627981.000029

=== Page 31 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257

=== Page 31 Image 1 (OCR) ===
ERR ES

Redacted

Tn ern EnE DS nSEnE DS EnSE RSENS SS ESEnESnSSESERSERESESnSSnSSHSSESESSSNSSUSESSnSSHSSISSnSSNSSUSEESSRESISSISSRSNSSHSIRSSEESHSSISSRSSNSSHSSRSSEESHS=NSSRSSNSSHSRSSRESHSSNSERISNSSHSSNSSESSHSSNSEnSSSSHSSNSSSOSISSNSERSESSHSnSSEOSISSNSERESNSSHSNSSEESHSSESERSSNSSHSESSESSHSSISERSSNSSHSNSERESHSSNSENSNSSHSRESESSHSSNSTSSSNESHSESERESNSSESTESNESHSIRESEOSNSSESESESNSDSSEnSSESSHSSNSISSSNS DE SnSSES DESDE SESESNSSOS

AAG-2627981.000030

=== Page 32 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257

=== Page 32 Image 1 (OCR) ===
ERR ES

Redacted

Tne Sane DS nSEnE ES DESEnSEnE SS EESEnESSSESERSEnESESnSSnSSESSESESSSNSSESESSESSHSSISTnSSNSSUSEISSRSSISEISSRSNSSHSIESSRESHSSNSSRSSNSSHSSRSSEESHSENSSRSSNSSISRSSRESHSSNSERISNSSHSIRSSESSHSSNSERSSSSHSSnSSEOSISSNSENSESSHSNSSROSISSNSIRESNSSHSNSSEESHSSHSERSSNSSHSESSRSSHSSESSRSSNSSHSESERESHSENSEnESNSSHSEESEOSESENSTSSSEESUSESERESNSSESTESSNESHSInESEOSHSENSSSESNSDSSEnSSEOSHSEISINSSNS DH SERSSESSSSDESESONSSIS

AAG-2627981 .000031

=== Page 33 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257

=== Page 33 Image 1 (OCR) ===
Be ee ee ee

Redacted

Cnn nen Ene rn SEnE SSE EnE SSE SEnE SOS S RENE SESE SEnE SESE SERENE SESE SERS SESE SERSSnSSESnSEESSOSSESERSnESOSNSSRESHSSE SIRENS SESnSSRESSSESSRESSSHSERSSRESHSSESERSNSSHSnSSnSSSSNSERSSNSSOSSESSSESHSSNSEnSSSSHSSESSnSSSSESSRESNSSISEASSRESSSESESSSNSSHSESSESSSSESSnSNESHSEISSRESSSNSInSSNSSUSSRSSROSESSNSTSSSNESESESSRESSSSSSTnSSSESHSnSSEESNSSNSESESNS DS SEnSSESSHSSNSISSNE SES EESSES DESDE SERSNSSISS

AAG-2627981.000032